Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors - Wikidata - wikimedia - TriplyDB

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

http://www.wikidata.org/entity/Q34960206

about

Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling Yessotoxin, a Marine Toxin, Exhibits Anti-Allergic and Anti-Tumoural Activities Inhibiting Melanoma Tumour Growth in a Preclinical Model A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis MS1 Peptide Ion Intensity Chromatograms in MS2 (SWATH) Data Independent Acquisitions. Improving Post Acquisition Analysis of Proteomic Experiments.Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.Inhibition of Acid Sphingomyelinase Depletes Cellular Phosphatidylserine and Mislocalizes K-Ras from the Plasma Membrane.Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome.Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors BRAF inhibitors: experience in thyroid cancer and general review of toxicity.The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.An Optimized Chromatographic Strategy for Multiplexing In Parallel Reaction Monitoring Mass Spectrometry: Insights from Quantitation of Activated Kinases.Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines.

P2860

Q26782222-6196AB9A-DF1F-4058-9228-7697D2F557BC Q27727733-3C13AE83-60F2-4695-85D0-074C7A785329 Q28555019-48539AB6-09CC-4A53-A534-F029CE8F45E9 Q28818626-C6922366-9717-49A0-A35A-2221D0D98ACA Q30953842-CC0102E5-CD48-4056-BC9C-C544B95756C0 Q33763540-6B5F630C-F5D7-4A7E-9C5A-4195F6DDD34A Q35797331-A71E6AFA-5A2C-41C4-9CDA-1191F817C479 Q36377576-A429137E-C10A-4F96-B5F2-3733BEB3F8D7 Q36432090-F08C462C-6414-4F93-A149-588130ACAEB0 Q36480870-1997353C-1D36-4E51-A9C5-4F68DD0A63F0 Q37262426-FF0B220C-137F-4057-8BCB-93F44FDBDE3A Q37514029-4A469C47-CE0D-487B-93BB-167D684D61F0 Q38281838-2EFF603F-FC55-4A32-8138-C288307B7448 Q38397326-49CA0F04-D35A-482E-92DF-A2F0191B6B31 Q38725367-3BFB9B7A-A981-403E-ABF2-0889D5D1CC3F Q38726735-A29E42B2-A7F8-4185-BBF6-91C820558ED1 Q38731795-E3C17173-4044-4D0F-AACD-31C09EA86390 Q38757495-7E7BDC54-841C-450C-BEDF-3B88933D319F Q38898974-44A62CFB-BC78-4460-AC4C-82EB43BD2085 Q41418283-EF182768-C29D-4843-B876-A4548E81B76A Q42382162-2334F246-C0AE-45AB-8415-3D24D23DE56E Q46132721-043A3E99-A570-4F1B-9C27-CF849E23426C Q48651245-DEB7DDE4-1067-401E-ACF9-544B209C992F Q52608453-89154F61-53D0-4F69-B814-60FB9B8753AB

P2860

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

http://www.wikidata.org/entity/Q34960206

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

@ast

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

@en

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

@nl

type

label

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

@ast

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

@en

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

@nl

prefLabel

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

@ast

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

@en

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

@nl

P1433

Q34960206-1C763621-8379-4A1E-8F0D-880E24D0C5BD

P1476

Q34960206-CD33CE91-C232-441A-BC6B-721419C7421A

P2093

Q34960206-088234A2-FE2A-47CD-A483-90D86C403D0A

Q34960206-3E4DD276-CBEF-44DD-8B5C-B11673266AF5

Q34960206-6DA38234-CB5A-453C-BD07-CBF8F452BF5C

Q34960206-6E2C3F7A-BEFB-4AFB-8CB8-AEB5550F198C

Q34960206-790A5D27-F9DE-4D1A-866F-DCBD3AB07A7B

Q34960206-822B3A2C-6066-4749-939A-458AB75C3459

Q34960206-96F93EFA-3DC1-4195-BBDF-F7632C99ABA5

Q34960206-E6DF72AD-90F2-4E78-AB85-75625C8CE893

Q34960206-EE5A06C5-DE28-4DB2-9570-3772324F0745

P2860

Q34960206-061A3CD9-6F9A-4F1C-A90E-DE3B7F2BA9B5

Q34960206-16CCC5E9-EEC0-49CC-AD8A-479DD258D5A6

Q34960206-1A90C689-174B-4853-8A21-B1E219FC6356

Q34960206-1D09EF96-4130-4501-8423-85FAD5275268

Q34960206-2191AA26-50C4-42E0-BA8C-2155C8C694AE

Q34960206-259D71E2-4B84-4974-B191-E592A2C0BEC4

Q34960206-279B1466-E671-4E08-A79B-7B0E2F9459C3

Q34960206-2DE27AD3-23F8-41A3-B54A-AE464FF851C9

Q34960206-352D2BE9-B55C-4CCA-A8A9-095A93B387ED

Q34960206-3FD5BB19-D14D-40C1-859F-E66762937C0B

P304

Q34960206-8EB349C0-06AE-4681-A19A-AA137B47C538

P31

Q34960206-3497D3EA-394E-4F34-8C54-F22B8F391BCA

P356

Q34960206-D489B17C-B84C-4F59-8E22-69C39BA8AF19

P433

Q34960206-202F6EFF-1AC1-4307-9943-37665A0140C8

P478

Q34960206-0DA59852-1C46-4360-91B9-DA288614175F

P50

Q34960206-DE6FA42D-EBA0-4F31-A0C6-34214BA99F0D

Q34960206-F92FA0FC-0091-4A91-9928-1B5A90BF8660

P577

Q34960206-407E9C31-E201-44B6-8375-8BE2288353AD

P5875

Q34960206-34EC1A7B-B1DF-49C2-8325-D763B8999E76

P698

Q34960206-6E77536E-898F-459F-B030-7D3891FFEF54

P932

Q34960206-FB109601-9140-4FE4-9AC4-DA7108AEEFA4

P356

J.CELREP.2014.07.010

P1433

P1476

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

@en

P2093

Alma L Burlingame

http://www.w3.org/2001/XMLSchema#string

Byron Hann

http://www.w3.org/2001/XMLSchema#string

Frank McCormick

http://www.w3.org/2001/XMLSchema#string

John D Gordan

http://www.w3.org/2001/XMLSchema#string

Kevan M Shokat

http://www.w3.org/2001/XMLSchema#string

Martin L Sos

http://www.w3.org/2001/XMLSchema#string

Megan Salt

http://www.w3.org/2001/XMLSchema#string

Rebecca S Levin

http://www.w3.org/2001/XMLSchema#string

Sourav Bandyopadhyay

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

An unbiased cell morphology-based screen for new, biologically active small molecules

The dynamic nature of the kinome

Tuning a Three-Component Reaction For Trapping Kinase Substrate Complexes

Discovery of pyrrolopyrimidine inhibitors of Akt

A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK

P304

1037-1048

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELREP.2014.07.010

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Juan A Oses-Prieto

James T. Webber

P577

2014-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264832368

http://www.w3.org/2001/XMLSchema#string

P698

25127139

http://www.w3.org/2001/XMLSchema#string

P932

4294625

http://www.w3.org/2001/XMLSchema#string